Abstract
Granulomatous hypophysitis (GrHy) is a rare inflammatory condition of the pituitary gland that can be idiopathic or secondary to systemic diseases like Crohn’s disease (CD). While corticosteroids are the standard first-line treatment, some cases are refractory. We report a case of a 43-year-old woman with CD and steroid-resistant GrHy who achieved complete clinical and radiographic resolution following treatment with the anti-tumor necrosis factor (TNF)-$\alpha$ agent, infliximab.
Introduction
Hypophysitis involves inflammation of the pituitary gland, leading to mass effect symptoms such as severe headaches and visual deficits, as well as life-threatening hormonal deficiencies. Granulomatous hypophysitis is a specific histologic subtype characterized by granulomas and multinucleated giant cells. When associated with Crohn’s disease, it represents an extra-intestinal manifestation of the systemic inflammatory process. Managing steroid-resistant cases remains a significant clinical challenge, necessitating personalized immunotherapy approaches.
Case Description
A 43-year-old woman with a 9-year history of ileal and colonic Crohn’s disease presented with severe headaches, visual disturbances, and symptoms of pituitary dysfunction, including secondary amenorrhea and fatigue. Initial hormonal testing confirmed hyperprolactinemia, secondary hypothyroidism, and adrenal insufficiency. MRI imaging revealed a 12 × 12 × 19 mm sellar mass abutting the optic chiasm, which was initially suspected to be a macroadenoma.
Histopathological Diagnosis
To differentiate the lesion from a neoplasm, the patient underwent an endoscopic transsphenoidal biopsy. The pathology revealed extensive granulomatous inflammation, confirming a diagnosis of granulomatous hypophysitis rather than a pituitary adenoma.
Therapeutic Intervention and Clinical Course
Following the diagnosis, the patient was started on high-dose prednisone. However, her symptoms worsened, and follow-up MRI showed an increase in the size of the inflammatory mass. She also developed symptoms of diabetes insipidus (polyuria and polydipsia).
Given her history of Crohn’s disease and the failure of corticosteroids, a personalized medicine approach was adopted. The patient was started on infliximab (an anti-TNF-$\alpha$ monoclonal antibody) in combination with azathioprine, therapies already indicated for her underlying Crohn's disease.
Results
The response to anti-TNF-$\alpha$ therapy was rapid and dramatic. Within three months, the patient's headaches and polyuria resolved, and her menstrual cycles resumed, indicating a partial restoration of the hypothalamic-pituitary-gonadal axis.
Long-term follow-up at 1.5 years confirmed the durable resolution of the pituitary mass. Although the patient eventually transitioned to adalimumab due to infliximab-induced plaque psoriasis, her pituitary condition remained in complete remission.
Conclusion
This case represents the first reported successful use of anti-TNF-$\alpha$ therapy for granulomatous hypophysitis. The shared inflammatory pathways between Crohn’s disease and GrHy suggest that TNF-$\alpha$ inhibition may be a potent therapeutic option for steroid-resistant cases, potentially extending to idiopathic forms of the disease where TNF-$\alpha$ plays a key role in granuloma formation.
Summary updated